Our products

Recordati Rare Diseases has a robust portfolio of therapies that target a wide range of medical conditions and are designed to meet the needs of underserved patient populations.

Filter by Product area
Filter by Country
BRAND NAME
INN
Country
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Austria
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Belgium
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Croatia
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Czech Republic
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Denmark
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Estonia
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Finland
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
France
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Germany
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Greece
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Hungary
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Iceland
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Ireland
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Italy
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Kosovo
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Lavtia
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Liechtenstein
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Lithuania
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Luxembourg
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Malta
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Norway
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Poland
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Portugal
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Qatar
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Romania
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Singapore
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Slovakia
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Slovenia
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Spain
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Sweden
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Switzerland
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
United Kingdom
CAPHOSOL
DIBASIC SODIUM PHOSPHATE, MONOBASIC SODIUM PHOSPHATE, CALCIUM CHLORIDE, SODIUM CHLORIDE
Usa
CARBAGLU
CARGLUMIC ACID
Oman
CARBAGLU
CARGLUMIC ACID
Argentina
CARBAGLU
CARGLUMIC ACID
Australia
CARBAGLU
CARGLUMIC ACID
Austria
CARBAGLU
CARGLUMIC ACID
Bahrain
CARBAGLU
CARGLUMIC ACID
Belgium
CARBAGLU
CARGLUMIC ACID
Brazil
CARBAGLU
CARGLUMIC ACID
Bulgaria
CARBAGLU
CARGLUMIC ACID
Canada
CARBAGLU
CARGLUMIC ACID
China
CARBAGLU
CARGLUMIC ACID
Colombia
CARBAGLU
CARGLUMIC ACID
Costa Rica
CARBAGLU
CARGLUMIC ACID
Croatia
CARBAGLU
CARGLUMIC ACID
Cyprus
CARBAGLU
CARGLUMIC ACID
Czech Republic
CARBAGLU
CARGLUMIC ACID
Denmark
CARBAGLU
CARGLUMIC ACID
Egypt
CARBAGLU
CARGLUMIC ACID
Estonia
CARBAGLU
CARGLUMIC ACID
Finland
CARBAGLU
CARGLUMIC ACID
France
CARBAGLU
CARGLUMIC ACID
Germany
CARBAGLU
CARGLUMIC ACID
Greece
CARBAGLU
CARGLUMIC ACID
Hong Kong
CARBAGLU
CARGLUMIC ACID
Hungary
CARBAGLU
CARGLUMIC ACID
Iceland
CARBAGLU
CARGLUMIC ACID
Iran
CARBAGLU
CARGLUMIC ACID
Ireland
CARBAGLU
CARGLUMIC ACID
Israel
CARBAGLU
CARGLUMIC ACID
Italy
CARBAGLU
CARGLUMIC ACID
Japan
CARBAGLU
CARGLUMIC ACID
Kuwait
CARBAGLU
CARGLUMIC ACID
Latvia
CARBAGLU
CARGLUMIC ACID
Libya
CARBAGLU
CARGLUMIC ACID
Lichtenstein
CARBAGLU
CARGLUMIC ACID
Lithuania
CARBAGLU
CARGLUMIC ACID
Luxembourg
CARBAGLU
CARGLUMIC ACID
Malta
CARBAGLU
CARGLUMIC ACID
Mexico
CARBAGLU
CARGLUMIC ACID
Morocco
CARBAGLU
CARGLUMIC ACID
Netherlands
CARBAGLU
CARGLUMIC ACID
Norway
CARBAGLU
CARGLUMIC ACID
Panama
CARBAGLU
CARGLUMIC ACID
Poland
CARBAGLU
CARGLUMIC ACID
Portugal
CARBAGLU
CARGLUMIC ACID
Qatar
CARBAGLU
CARGLUMIC ACID
Romania
CARBAGLU
CARGLUMIC ACID
Russia
CARBAGLU
CARGLUMIC ACID
Saudi Arabia
CARBAGLU
CARGLUMIC ACID
Slovakia
CARBAGLU
CARGLUMIC ACID
Slovenia
CARBAGLU
CARGLUMIC ACID
South Africa
CARBAGLU
CARGLUMIC ACID
South Korea
CARBAGLU
CARGLUMIC ACID
Spain
CARBAGLU
CARGLUMIC ACID
Sweden
CARBAGLU
CARGLUMIC ACID
Switzerland
CARBAGLU
CARGLUMIC ACID
Taiwan
CARBAGLU
CARGLUMIC ACID
Thailand
CARBAGLU
CARGLUMIC ACID
Turkey
CARBAGLU
CARGLUMIC ACID
United Arab Emirates
CARBAGLU
CARGLUMIC ACID
Usa
COSMEGEN
DACTINOMYCIN
South Africa
COSMEGEN
DACTINOMYCIN
Ukraine
COSMEGEN
DACTINOMYCIN
Argentina
COSMEGEN
DACTINOMYCIN
Australia
COSMEGEN
DACTINOMYCIN
Canada
COSMEGEN
DACTINOMYCIN
France
COSMEGEN
DACTINOMYCIN
Italy
COSMEGEN
DACTINOMYCIN
Mexico
COSMEGEN
DACTINOMYCIN
New Zealand
COSMEGEN
DACTINOMYCIN
Russia
COSMEGEN
DACTINOMYCIN
Usa
COSMEGEN(COSMEGEN LYOVAC )
DACTINOMYCIN
Egypt
COSMEGEN (COSMEGEN LYOVAC )
DACTINOMYCIN
Iran
COSMEGEN(COSMEGEN LYOVAC )
DACTINOMYCIN
Malta
COSMEGEN(COSMEGEN LYOVAC )
DACTINOMYCIN
Thailand
COSMEGEN(COSMEGEN LYOVAC )
DACTINOMYCIN
United Arab Emirates
COSMEGEN(COSMEGEN LYOVAC )
DACTINOMYCIN
United Kingdom
COSMEGEN(LYOVAC COSMEGEN)
DACTINOMYCIN
Germany
CYSTADANE
ANHYDROUS BETAINE
Argentina
CYSTADANE
ANHYDROUS BETAINE
Australia
CYSTADANE
ANHYDROUS BETAINE
Austria
CYSTADANE
ANHYDROUS BETAINE
Bahrain
CYSTADANE
ANHYDROUS BETAINE
Belgium
CYSTADANE
ANHYDROUS BETAINE
Bulgaria
CYSTADANE
ANHYDROUS BETAINE
Canada
CYSTADANE
ANHYDROUS BETAINE
Colombia
CYSTADANE
ANHYDROUS BETAINE
Croatia
CYSTADANE
ANHYDROUS BETAINE
Cyprus
CYSTADANE
ANHYDROUS BETAINE
Czech Republic
CYSTADANE
ANHYDROUS BETAINE
Denmark
CYSTADANE
ANHYDROUS BETAINE
Estonia
CYSTADANE
ANHYDROUS BETAINE
Finland
CYSTADANE
ANHYDROUS BETAINE
France
CYSTADANE
ANHYDROUS BETAINE
Germany
CYSTADANE
ANHYDROUS BETAINE
Greece
CYSTADANE
ANHYDROUS BETAINE
Hungary
CYSTADANE
ANHYDROUS BETAINE
Iceland
CYSTADANE
ANHYDROUS BETAINE
Iran
CYSTADANE
ANHYDROUS BETAINE
Ireland
CYSTADANE
ANHYDROUS BETAINE
Israel
CYSTADANE
ANHYDROUS BETAINE
Italy
CYSTADANE
ANHYDROUS BETAINE
Japan
CYSTADANE
ANHYDROUS BETAINE
Kuwait
CYSTADANE
ANHYDROUS BETAINE
Latvia
CYSTADANE
ANHYDROUS BETAINE
Lichtenstein
CYSTADANE
ANHYDROUS BETAINE
Lithuania
CYSTADANE
ANHYDROUS BETAINE
Luxembourg
CYSTADANE
ANHYDROUS BETAINE
Malta
CYSTADANE
ANHYDROUS BETAINE
Mexico
CYSTADANE
ANHYDROUS BETAINE
Netherlands
CYSTADANE
ANHYDROUS BETAINE
New Zealand
CYSTADANE
ANHYDROUS BETAINE
Norway
CYSTADANE
ANHYDROUS BETAINE
Poland
CYSTADANE
ANHYDROUS BETAINE
Portugal
CYSTADANE
ANHYDROUS BETAINE
Qatar
CYSTADANE
ANHYDROUS BETAINE
Romania
CYSTADANE
ANHYDROUS BETAINE
Slovakia
CYSTADANE
ANHYDROUS BETAINE
Slovenia
CYSTADANE
ANHYDROUS BETAINE
South Korea
CYSTADANE
ANHYDROUS BETAINE
Spain
CYSTADANE
ANHYDROUS BETAINE
Sweden
CYSTADANE
ANHYDROUS BETAINE
United Arab Emirates
CYSTADANE
ANHYDROUS BETAINE
United Kingdom
CYSTADANE
ANHYDROUS BETAINE
Usa
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Argentina
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Australia
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Austria
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Bahrain
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Belgium
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Bulgaria
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Canada
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Colombia
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Croatia
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Cyprus
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Czech Republic
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Denmark
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Estonia
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Finland
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
France
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Germany
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Greece
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Hungary
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Iceland
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Ireland
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Israel
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Italy
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Japan
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Kuwait
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Latvia
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Lichtenstein
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Lithuania
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Luxembourg
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Malta
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Mexico
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Netherlands
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Norway
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Oman
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Poland
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Portugal
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Romania
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Slovakia
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Slovenia
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Spain
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Sweden
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Switzerland
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
United Arab Emirates
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
United Kingdom
CYSTADROPS
CYSTEAMINE HYDROCHLORIDE
Usa
CYSTAGON 150 MG
CYSTEAMINE
Colombia
CYSTAGON 50 MG
CYSTEAMINE
Colombia
CYSTAGON
CYSTEAMINE
Algeria
CYSTAGON
CYSTEAMINE
Argentina
CYSTAGON
CYSTEAMINE
Austria
CYSTAGON
CYSTEAMINE
Belgium
CYSTAGON
CYSTEAMINE
Bulgaria
CYSTAGON
CYSTEAMINE
Croatia
CYSTAGON
CYSTEAMINE
Cyprus
CYSTAGON
CYSTEAMINE
Czech Republic
CYSTAGON
CYSTEAMINE
Denmark
CYSTAGON
CYSTEAMINE
Estonia
CYSTAGON
CYSTEAMINE
Finland
CYSTAGON
CYSTEAMINE
France
CYSTAGON
CYSTEAMINE
Germany
CYSTAGON
CYSTEAMINE
Greece
CYSTAGON
CYSTEAMINE
Hungary
CYSTAGON
CYSTEAMINE
Iceland
CYSTAGON
CYSTEAMINE
Iran
CYSTAGON
CYSTEAMINE
Ireland
CYSTAGON
CYSTEAMINE
Israel
CYSTAGON
CYSTEAMINE
Italy
CYSTAGON
CYSTEAMINE
Kuwait
CYSTAGON
CYSTEAMINE
Latvia
CYSTAGON
CYSTEAMINE
Lichtenstein
CYSTAGON
CYSTEAMINE
Lithuania
CYSTAGON
CYSTEAMINE
Luxembourg
CYSTAGON
CYSTEAMINE
Malta
CYSTAGON
CYSTEAMINE
Mexico
CYSTAGON
CYSTEAMINE
Netherlands
CYSTAGON
CYSTEAMINE
Norway
CYSTAGON
CYSTEAMINE
Panama
CYSTAGON
CYSTEAMINE
Poland
CYSTAGON
CYSTEAMINE
Portugal
CYSTAGON
CYSTEAMINE
Romania
CYSTAGON
CYSTEAMINE
Slovakia
CYSTAGON
CYSTEAMINE
Slovenia
CYSTAGON
CYSTEAMINE
Spain
CYSTAGON
CYSTEAMINE
Sweden
CYSTAGON
CYSTEAMINE
United Arab Emirates
CYSTAGON
CYSTEAMINE
United Kingdom
DINUTUXIMAB BETA APEIRON
DINUTUXIMAB BETA
Israel
ENJAYMO
SUTIMLIMAB
Austria
ENJAYMO
SUTIMLIMAB
Belgium
ENJAYMO
SUTIMLIMAB
Bulgaria
ENJAYMO
SUTIMLIMAB
Croatia
ENJAYMO
SUTIMLIMAB
Cyprus
ENJAYMO
SUTIMLIMAB
Czech Republic
ENJAYMO
SUTIMLIMAB
Denmark
ENJAYMO
SUTIMLIMAB
Estonia
ENJAYMO
SUTIMLIMAB
Finland
ENJAYMO
SUTIMLIMAB
France
ENJAYMO
SUTIMLIMAB
Germany
ENJAYMO
SUTIMLIMAB
Greece
ENJAYMO
SUTIMLIMAB
Hungary
ENJAYMO
SUTIMLIMAB
Iceland
ENJAYMO
SUTIMLIMAB
Ireland
ENJAYMO
SUTIMLIMAB
Israel
ENJAYMO
SUTIMLIMAB
Italy
ENJAYMO
SUTIMLIMAB
Japan
ENJAYMO
SUTIMLIMAB
Latvia
ENJAYMO
SUTIMLIMAB
Liechtenstein
ENJAYMO
SUTIMLIMAB
Lithuania
ENJAYMO
SUTIMLIMAB
Luxembourg
ENJAYMO
SUTIMLIMAB
Malta
ENJAYMO
SUTIMLIMAB
Netherlands
ENJAYMO
SUTIMLIMAB
Norway
ENJAYMO
SUTIMLIMAB
Poland
ENJAYMO
SUTIMLIMAB
Portugal
ENJAYMO
SUTIMLIMAB
Romania
ENJAYMO
SUTIMLIMAB
Slovakia
ENJAYMO
SUTIMLIMAB
Slovenia
ENJAYMO
SUTIMLIMAB
South Korea
ENJAYMO
SUTIMLIMAB
Spain
ENJAYMO
SUTIMLIMAB
Sweden
ENJAYMO
SUTIMLIMAB
Switzerland
ENJAYMO
SUTIMLIMAB-JOME
Usa
FOTIVDA 1340 MCG
TIVOZANIB
Austria
FOTIVDA 1340 MCG
TIVOZANIB
Belgium
FOTIVDA 1340 MCG
TIVOZANIB
Bulgaria
FOTIVDA 1340 MCG
TIVOZANIB
Croatia
FOTIVDA 1340 MCG
TIVOZANIB
Cyprus
FOTIVDA 1340 MCG
TIVOZANIB
Czech Republic
FOTIVDA 1340 MCG
TIVOZANIB
Denmark
FOTIVDA 1340 MCG
TIVOZANIB
Estonia
FOTIVDA 1340 MCG
TIVOZANIB
Finland
FOTIVDA 1340 MCG
TIVOZANIB
France
FOTIVDA 1340 MCG
TIVOZANIB
Germany
FOTIVDA 1340 MCG
TIVOZANIB
Greece
FOTIVDA 1340 MCG
TIVOZANIB
Hungary
FOTIVDA 1340 MCG
TIVOZANIB
Iceland
FOTIVDA 1340 MCG
TIVOZANIB
Ireland
FOTIVDA 1340 MCG
TIVOZANIB
Italy
FOTIVDA 1340 MCG
TIVOZANIB
Latvia
FOTIVDA 1340 MCG
TIVOZANIB
Liechtenstein
FOTIVDA 1340 MCG
TIVOZANIB
Lithuania
FOTIVDA 1340 MCG
TIVOZANIB
Luxembourg
FOTIVDA 1340 MCG
TIVOZANIB
Malta
FOTIVDA 1340 MCG
TIVOZANIB
Netherlands
FOTIVDA 1340 MCG
TIVOZANIB
Norway
FOTIVDA 1340 MCG
TIVOZANIB
Poland
FOTIVDA 1340 MCG
TIVOZANIB
Portugal
FOTIVDA 1340 MCG
TIVOZANIB
Romania
FOTIVDA 1340 MCG
TIVOZANIB
Slovakia
FOTIVDA 1340 MCG
TIVOZANIB
Slovenia
FOTIVDA 1340 MCG
TIVOZANIB
Spain
FOTIVDA 1340 MCG
TIVOZANIB
Sweden
FOTIVDA 1340 MCG
TIVOZANIB
United Kingdom
FOTIVDA 890 MCG
TIVOZANIB
Austria
FOTIVDA 890 MCG
TIVOZANIB
Belgium
FOTIVDA 890 MCG
TIVOZANIB
Bulgaria
FOTIVDA 890 MCG
TIVOZANIB
Croatia
FOTIVDA 890 MCG
TIVOZANIB
Cyprus
FOTIVDA 890 MCG
TIVOZANIB
Czech Republic
FOTIVDA 890 MCG
TIVOZANIB
Denmark
FOTIVDA 890 MCG
TIVOZANIB
Estonia
FOTIVDA 890 MCG
TIVOZANIB
Finland
FOTIVDA 890 MCG
TIVOZANIB
France
FOTIVDA 890 MCG
TIVOZANIB
Germany
FOTIVDA 890 MCG
TIVOZANIB
Greece
FOTIVDA 890 MCG
TIVOZANIB
Hungary
FOTIVDA 890 MCG
TIVOZANIB
Iceland
FOTIVDA 890 MCG
TIVOZANIB
Ireland
FOTIVDA 890 MCG
TIVOZANIB
Italy
FOTIVDA 890 MCG
TIVOZANIB
Latvia
FOTIVDA 890 MCG
TIVOZANIB
Liechtenstein
FOTIVDA 890 MCG
TIVOZANIB
Lithuania
FOTIVDA 890 MCG
TIVOZANIB
Luxembourg
FOTIVDA 890 MCG
TIVOZANIB
Malta
FOTIVDA 890 MCG
TIVOZANIB
Netherlands
FOTIVDA 890 MCG
TIVOZANIB
Norway
FOTIVDA 890 MCG
TIVOZANIB
Poland
FOTIVDA 890 MCG
TIVOZANIB
Portugal
FOTIVDA 890 MCG
TIVOZANIB
Romania
FOTIVDA 890 MCG
TIVOZANIB
Slovakia
FOTIVDA 890 MCG
TIVOZANIB
Slovenia
FOTIVDA 890 MCG
TIVOZANIB
Spain
FOTIVDA 890 MCG
TIVOZANIB
Sweden
FOTIVDA 890 MCG
TIVOZANIB
United Kingdom
ISTURISA
OSILODROSTAT
Bahrain
ISTURISA
OSILODROSTAT
Australia
ISTURISA
OSILODROSTAT
Austria
ISTURISA
OSILODROSTAT
Belgium
ISTURISA
OSILODROSTAT
Brazil
ISTURISA
OSILODROSTAT
Bulgaria
ISTURISA
OSILODROSTAT
China
ISTURISA
OSILODROSTAT
Colombia
ISTURISA
OSILODROSTAT
Croatia
ISTURISA
OSILODROSTAT
Cyprus
ISTURISA
OSILODROSTAT
Czech Republic
ISTURISA
OSILODROSTAT
Denmark
ISTURISA
OSILODROSTAT
Estonia
ISTURISA
OSILODROSTAT
Finland
ISTURISA
OSILODROSTAT
France
ISTURISA
OSILODROSTAT
Germany
ISTURISA
OSILODROSTAT
Greece
ISTURISA
OSILODROSTAT
Hungary
ISTURISA
OSILODROSTAT
Iceland
ISTURISA
OSILODROSTAT
Ireland
ISTURISA
OSILODROSTAT
Israel
ISTURISA
OSILODROSTAT
Italy
ISTURISA
OSILODROSTAT
Japan
ISTURISA
OSILODROSTAT
Kuwait
ISTURISA
OSILODROSTAT
Latvia
ISTURISA
OSILODROSTAT
Lichtenstein
ISTURISA
OSILODROSTAT
Lithuania
ISTURISA
OSILODROSTAT
Luxembourg
ISTURISA
OSILODROSTAT
Malta
ISTURISA
OSILODROSTAT
Netherlands
ISTURISA
OSILODROSTAT
Norway
ISTURISA
OSILODROSTAT
Poland
ISTURISA
OSILODROSTAT
Portugal
ISTURISA
OSILODROSTAT
Romania
ISTURISA
OSILODROSTAT
Slovakia
ISTURISA
OSILODROSTAT
Slovenia
ISTURISA
OSILODROSTAT
South Korea
ISTURISA
OSILODROSTAT
Spain
ISTURISA
OSILODROSTAT
Sweden
ISTURISA
OSILODROSTAT
Switzerland
ISTURISA
OSILODROSTAT
Uae
ISTURISA
OSILODROSTAT
United Kingdom
ISTURISA
OSILODROSTAT
Usa
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Argentina
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Bahrain
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Canada
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Colombia
LEDAGA
CHLORMETHINE HYDROCHLORIDE
France
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Kuwait
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Mexico
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Oman
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Qatar
LEDAGA
CHLORMETHINE HYDROCHLORIDE
South Africa
LEDAGA
CHLORMETHINE HYDROCHLORIDE
Switzerland
LEDAGA
CHLORMETHINE HYDROCHLORIDE
United Arab Emirates
LEDAGA
CHLORMETHINE HYDROCHLORIDE
United Kingdom
NEOPROFEN
IBUPROFEN LYSINE
Brazil
NEOPROFEN
IBUPROFEN LYSINE
Japan
NORMOSANG HUMAN HEMIN ORPHAN EUROPE
HUMAN HEMIN
Poland
NORMOSANG
HUMAN HEMIN
Argentina
NORMOSANG
HUMAN HEMIN
Austria
NORMOSANG
HUMAN HEMIN
Belgium
NORMOSANG
HUMAN HEMIN
Croatia
NORMOSANG
HUMAN HEMIN
Cyprus
NORMOSANG
HUMAN HEMIN
Czech Republic
NORMOSANG
HUMAN HEMIN
Denmark
NORMOSANG
HUMAN HEMIN
Estonia
NORMOSANG
HUMAN HEMIN
Finland
NORMOSANG
HUMAN HEMIN
France
NORMOSANG
HUMAN HEMIN
Germany
NORMOSANG
HUMAN HEMIN
Greece
NORMOSANG
HUMAN HEMIN
Hong Kong
NORMOSANG
HUMAN HEMIN
Hungary
NORMOSANG
HUMAN HEMIN
Iceland
NORMOSANG
HUMAN HEMIN
Ireland
NORMOSANG
HUMAN HEMIN
Italy
NORMOSANG
HUMAN HEMIN
Japan
NORMOSANG
HUMAN HEMIN
Kuwait
NORMOSANG
HUMAN HEMIN
Latvia
NORMOSANG
HUMAN HEMIN
Lithuania
NORMOSANG
HUMAN HEMIN
Luxembourg
NORMOSANG
HUMAN HEMIN
Malta
NORMOSANG
HUMAN HEMIN
Mexico
NORMOSANG
HUMAN HEMIN
Namibia
NORMOSANG
HUMAN HEMIN
Netherlands
NORMOSANG
HUMAN HEMIN
Norway
NORMOSANG
HUMAN HEMIN
Peru
NORMOSANG
HUMAN HEMIN
Portugal
NORMOSANG
HUMAN HEMIN
Russia
NORMOSANG
HUMAN HEMIN
Saudi Arabia
NORMOSANG
HUMAN HEMIN
Serbia
NORMOSANG
HUMAN HEMIN
Slovakia
NORMOSANG
HUMAN HEMIN
Slovenia
NORMOSANG
HUMAN HEMIN
South Africa
NORMOSANG
HUMAN HEMIN
South Korea
NORMOSANG
HUMAN HEMIN
Spain
NORMOSANG
HUMAN HEMIN
Sweden
NORMOSANG
HUMAN HEMIN
Switzerland
NORMOSANG
HUMAN HEMIN
Taiwan
NORMOSANG
HUMAN HEMIN
United Arab Emirates
NORMOSANG
HUMAN HEMIN
United Kingdom
PANHEMATIN
HUMAN HEMIN
Brazil
PANHEMATIN
HUMAN HEMIN
Canada
PANHEMATIN
HUMAN HEMIN
Colombia
PANHEMATIN
HUMAN HEMIN
Usa
PEDEA
IBUPROFEN
Australia
PEDEA
IBUPROFEN
Austria
PEDEA
IBUPROFEN
Bahrain
PEDEA
IBUPROFEN
Belarus
PEDEA
IBUPROFEN
Belgium
PEDEA
IBUPROFEN
Bulgaria
PEDEA
IBUPROFEN
Colombia
PEDEA
IBUPROFEN
Costa Rica
PEDEA
IBUPROFEN
Croatia
PEDEA
IBUPROFEN
Cyprus
PEDEA
IBUPROFEN
Czech Republic
PEDEA
IBUPROFEN
Denmark
PEDEA
IBUPROFEN
Estonia
PEDEA
IBUPROFEN
Finland
PEDEA
IBUPROFEN
France
PEDEA
IBUPROFEN
Germany
PEDEA
IBUPROFEN
Greece
PEDEA
IBUPROFEN
Hong Kong
PEDEA
IBUPROFEN
Hungary
PEDEA
IBUPROFEN
Iceland
PEDEA
IBUPROFEN
Iran
PEDEA
IBUPROFEN
Ireland
PEDEA
IBUPROFEN
Italy
PEDEA
IBUPROFEN
Kazakhstan
PEDEA
IBUPROFEN
Kuwait
PEDEA
IBUPROFEN
Latvia
PEDEA
IBUPROFEN
Lichtenstein
PEDEA
IBUPROFEN
Lithuania
PEDEA
IBUPROFEN
Luxembourg
PEDEA
IBUPROFEN
Malta
PEDEA
IBUPROFEN
Mexico
PEDEA
IBUPROFEN
Namibia
PEDEA
IBUPROFEN
Netherlands
PEDEA
IBUPROFEN
Norway
PEDEA
IBUPROFEN
Panama
PEDEA
IBUPROFEN
Peru
PEDEA
IBUPROFEN
Poland
PEDEA
IBUPROFEN
Portugal
PEDEA
IBUPROFEN
Romania
PEDEA
IBUPROFEN
Russia
PEDEA
IBUPROFEN
Saudi Arabia
PEDEA
IBUPROFEN
Serbia
PEDEA
IBUPROFEN
Slovakia
PEDEA
IBUPROFEN
Slovenia
PEDEA
IBUPROFEN
South Africa
PEDEA
IBUPROFEN
South Korea
PEDEA
IBUPROFEN
Spain
PEDEA
IBUPROFEN
Sweden
PEDEA
IBUPROFEN
Uae
PEDEA
IBUPROFEN
United Kingdom
QARZIBA
DINUTUXIMAB BETA
Australia
QARZIBA
DINUTUXIMAB BETA
Austria
QARZIBA
DINUTUXIMAB BETA
Belgium
QARZIBA
DINUTUXIMAB BETA
Brazil
QARZIBA
DINUTUXIMAB BETA
Bulgaria
QARZIBA
DINUTUXIMAB BETA
China
QARZIBA
DINUTUXIMAB BETA
Croatia
QARZIBA
DINUTUXIMAB BETA
Cyprus
QARZIBA
DINUTUXIMAB BETA
Czech Republic
QARZIBA
DINUTUXIMAB BETA
Denmark
QARZIBA
DINUTUXIMAB BETA
Estonia
QARZIBA
DINUTUXIMAB BETA
Finland
QARZIBA
DINUTUXIMAB BETA
France
QARZIBA
DINUTUXIMAB BETA
Germany
QARZIBA
DINUTUXIMAB BETA
Greece
QARZIBA
DINUTUXIMAB BETA
Hong Kong
QARZIBA
DINUTUXIMAB BETA
Hungary
QARZIBA
DINUTUXIMAB BETA
Iceland
QARZIBA
DINUTUXIMAB BETA
Ireland
QARZIBA
DINUTUXIMAB BETA
Italy
QARZIBA
DINUTUXIMAB BETA
Latvia
QARZIBA
DINUTUXIMAB BETA
Liechtenstein
QARZIBA
DINUTUXIMAB BETA
Lithuania
QARZIBA
DINUTUXIMAB BETA
Luxembourg
QARZIBA
DINUTUXIMAB BETA
Malta
QARZIBA
DINUTUXIMAB BETA
Netherlands
QARZIBA
DINUTUXIMAB BETA
Norway
QARZIBA
DINUTUXIMAB BETA
Poland
QARZIBA
DINUTUXIMAB BETA
Portugal
QARZIBA
DINUTUXIMAB BETA
Romania
QARZIBA
DINUTUXIMAB BETA
Russia
QARZIBA
DINUTUXIMAB BETA
Slovakia
QARZIBA
DINUTUXIMAB BETA
Slovenia
QARZIBA
DINUTUXIMAB BETA
South Korea
QARZIBA
DINUTUXIMAB BETA
Spain
QARZIBA
DINUTUXIMAB BETA
Sweden
QARZIBA
DINUTUXIMAB BETA
Switzerland
QARZIBA
DINUTUXIMAB BETA
Taiwan
QARZIBA
DINUTUXIMAB BETA
Uae
QARZIBA
DINUTUXIMAB BETA
United Kingdom
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Bahrain
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Kuwait
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Qatar
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Argentina
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Australia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Austria
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Belgium
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Brazil
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Bulgaria
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Canada
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Chile
SIGNIFOR LAR
PASIREOTIDE PAMOATE
China
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Colombia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Costa Rica
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Croatia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Cyprus
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Czech Republic
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Denmark
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Ecuador
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Estonia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Finland
SIGNIFOR LAR
PASIREOTIDE PAMOATE
France
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Germany
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Greece
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Guatemala
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Hong Kong
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Hungary
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Iceland
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Ireland
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Israel
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Italy
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Japan
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Kazakhstan
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Latvia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Lichtenstein
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Lithuania
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Luxembourg
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Malaysia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Malta
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Morocco
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Netherlands
SIGNIFOR LAR
PASIREOTIDE PAMOATE
New Zealand
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Norway
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Panama
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Peru
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Poland
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Portugal
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Romania
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Serbia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Singapore
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Slovakia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Slovenia
SIGNIFOR LAR
PASIREOTIDE PAMOATE
South Africa
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Spain
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Sweden
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Switzerland
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Taiwan
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Ukraine
SIGNIFOR LAR
PASIREOTIDE PAMOATE
United Arab Emirates
SIGNIFOR LAR
PASIREOTIDE PAMOATE
United Kingdom
SIGNIFOR LAR
PASIREOTIDE PAMOATE
Usa
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Argentina
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Australia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Austria
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Belarus
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Belgium
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Brazil
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Bulgaria
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Canada
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Colombia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Croatia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Cyprus
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Czech Republic
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Denmark
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Ecuador
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Egypt
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Estonia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Finland
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
France
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Germany
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Greece
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Hungary
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Iceland
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Ireland
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Israel
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Italy
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Kazakhstan
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Latvia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Lebanon
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Lichtenstein
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Lithuania
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Luxembourg
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Malta
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Mexico
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Netherlands
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
New Zealand
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Norway
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Poland
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Portugal
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Romania
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Russia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Serbia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Slovakia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Slovenia
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Spain
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Sweden
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Switzerland
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Taiwan
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Turkey
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
United Kingdom
SIGNIFOR LIAM
PASIREOTIDE DIASPARTATE
Usa
SYLVANT 100 MG
SILTUXIMAB
Argentina
SYLVANT 100 MG
SILTUXIMAB
Australia
SYLVANT 100 MG
SILTUXIMAB
Austria
SYLVANT 100 MG
SILTUXIMAB
Belgium
SYLVANT 100 MG
SILTUXIMAB
Brazil
SYLVANT 100 MG
SILTUXIMAB
Bulgaria
SYLVANT 100 MG
SILTUXIMAB
Canada
SYLVANT 100 MG
SILTUXIMAB
China
SYLVANT 100 MG
SILTUXIMAB
Croatia
SYLVANT 100 MG
SILTUXIMAB
Cyprus
SYLVANT 100 MG
SILTUXIMAB
Czech Republic
SYLVANT 100 MG
SILTUXIMAB
Denmark
SYLVANT 100 MG
SILTUXIMAB
Estonia
SYLVANT 100 MG
SILTUXIMAB
Finland
SYLVANT 100 MG
SILTUXIMAB
France
SYLVANT 100 MG
SILTUXIMAB
Germany
SYLVANT 100 MG
SILTUXIMAB
Greece
SYLVANT 100 MG
SILTUXIMAB
Hong Kong
SYLVANT 100 MG
SILTUXIMAB
Hungary
SYLVANT 100 MG
SILTUXIMAB
Iceland
SYLVANT 100 MG
SILTUXIMAB
Ireland
SYLVANT 100 MG
SILTUXIMAB
Israel
SYLVANT 100 MG
SILTUXIMAB
Italy
SYLVANT 100 MG
SILTUXIMAB
Latvia
SYLVANT 100 MG
SILTUXIMAB
Liechtenstein
SYLVANT 100 MG
SILTUXIMAB
Lituania
SYLVANT 100 MG
SILTUXIMAB
Luxembourg
SYLVANT 100 MG
SILTUXIMAB
Malaysia
SYLVANT 100 MG
SILTUXIMAB
Malta
SYLVANT 100 MG
SILTUXIMAB
Mexico
SYLVANT 100 MG
SILTUXIMAB
Netherlands
SYLVANT 100 MG
SILTUXIMAB
New Zealand
SYLVANT 100 MG
SILTUXIMAB
Norway
SYLVANT 100 MG
SILTUXIMAB
Philippines
SYLVANT 100 MG
SILTUXIMAB
Poland
SYLVANT 100 MG
SILTUXIMAB
Portugal
SYLVANT 100 MG
SILTUXIMAB
Romania
SYLVANT 100 MG
SILTUXIMAB
Singapore
SYLVANT 100 MG
SILTUXIMAB
Slovakia
SYLVANT 100 MG
SILTUXIMAB
Slovenia
SYLVANT 100 MG
SILTUXIMAB
South Africa
SYLVANT 100 MG
SILTUXIMAB
South Korea
SYLVANT 100 MG
SILTUXIMAB
Spain
SYLVANT 100 MG
SILTUXIMAB
Sweden
SYLVANT 100 MG
SILTUXIMAB
Switzerland
SYLVANT 100 MG
SILTUXIMAB
Taiwan
SYLVANT 100 MG
SILTUXIMAB
United Kingdom
SYLVANT 100 MG
SILTUXIMAB
Usa
SYLVANT 400 MG
SILTUXIMAB
Malaysia
SYLVANT 400 MG
SILTUXIMAB
Argentina
SYLVANT 400 MG
SILTUXIMAB
Australia
SYLVANT 400 MG
SILTUXIMAB
Austria
SYLVANT 400 MG
SILTUXIMAB
Belgium
SYLVANT 400 MG
SILTUXIMAB
Brazil
SYLVANT 400 MG
SILTUXIMAB
Bulgaria
SYLVANT 400 MG
SILTUXIMAB
Canada
SYLVANT 400 MG
SILTUXIMAB
China
SYLVANT 400 MG
SILTUXIMAB
Croatia
SYLVANT 400 MG
SILTUXIMAB
Cyprus
SYLVANT 400 MG
SILTUXIMAB
Czech Republic
SYLVANT 400 MG
SILTUXIMAB
Denmark
SYLVANT 400 MG
SILTUXIMAB
Estonia
SYLVANT 400 MG
SILTUXIMAB
Finland
SYLVANT 400 MG
SILTUXIMAB
France
SYLVANT 400 MG
SILTUXIMAB
Germany
SYLVANT 400 MG
SILTUXIMAB
Greece
SYLVANT 400 MG
SILTUXIMAB
Hong Kong
SYLVANT 400 MG
SILTUXIMAB
Hungary
SYLVANT 400 MG
SILTUXIMAB
Iceland
SYLVANT 400 MG
SILTUXIMAB
Ireland
SYLVANT 400 MG
SILTUXIMAB
Israel
SYLVANT 400 MG
SILTUXIMAB
Italy
SYLVANT 400 MG
SILTUXIMAB
Latvia
SYLVANT 400 MG
SILTUXIMAB
Liechtenstein
SYLVANT 400 MG
SILTUXIMAB
Lituania
SYLVANT 400 MG
SILTUXIMAB
Luxembourg
SYLVANT 400 MG
SILTUXIMAB
Malta
SYLVANT 400 MG
SILTUXIMAB
Mexico
SYLVANT 400 MG
SILTUXIMAB
Netherlands
SYLVANT 400 MG
SILTUXIMAB
New Zealand
SYLVANT 400 MG
SILTUXIMAB
Norway
SYLVANT 400 MG
SILTUXIMAB
Philippines
SYLVANT 400 MG
SILTUXIMAB
Poland
SYLVANT 400 MG
SILTUXIMAB
Portugal
SYLVANT 400 MG
SILTUXIMAB
Romania
SYLVANT 400 MG
SILTUXIMAB
Singapore
SYLVANT 400 MG
SILTUXIMAB
Slovakia
SYLVANT 400 MG
SILTUXIMAB
Slovenia
SYLVANT 400 MG
SILTUXIMAB
South Africa
SYLVANT 400 MG
SILTUXIMAB
South Korea
SYLVANT 400 MG
SILTUXIMAB
Spain
SYLVANT 400 MG
SILTUXIMAB
Sweden
SYLVANT 400 MG
SILTUXIMAB
Switzerland
SYLVANT 400 MG
SILTUXIMAB
Taiwan
SYLVANT 400 MG
SILTUXIMAB
United Kingdom
SYLVANT 400 MG
SILTUXIMAB
Usa
VEDROP
TOCOFERSOLAN
Austria
VEDROP
TOCOFERSOLAN
Belgium
VEDROP
TOCOFERSOLAN
Bulgaria
VEDROP
TOCOFERSOLAN
Croatia
VEDROP
TOCOFERSOLAN
Cyprus
VEDROP
TOCOFERSOLAN
Czech Republic
VEDROP
TOCOFERSOLAN
Denmark
VEDROP
TOCOFERSOLAN
Estonia
VEDROP
TOCOFERSOLAN
Finland
VEDROP
TOCOFERSOLAN
France
VEDROP
TOCOFERSOLAN
Germany
VEDROP
TOCOFERSOLAN
Greece
VEDROP
TOCOFERSOLAN
Hungary
VEDROP
TOCOFERSOLAN
Iceland
VEDROP
TOCOFERSOLAN
Ireland
VEDROP
TOCOFERSOLAN
Italy
VEDROP
TOCOFERSOLAN
Kuwait
VEDROP
TOCOFERSOLAN
Latvia
VEDROP
TOCOFERSOLAN
Lichtenstein
VEDROP
TOCOFERSOLAN
Lithuania
VEDROP
TOCOFERSOLAN
Luxembourg
VEDROP
TOCOFERSOLAN
Malta
VEDROP
TOCOFERSOLAN
Netherlands
VEDROP
TOCOFERSOLAN
Norway
VEDROP
TOCOFERSOLAN
Poland
VEDROP
TOCOFERSOLAN
Portugal
VEDROP
TOCOFERSOLAN
Romania
VEDROP
TOCOFERSOLAN
Slovakia
VEDROP
TOCOFERSOLAN
Slovenia
VEDROP
TOCOFERSOLAN
Spain
VEDROP
TOCOFERSOLAN
Sweden
VEDROP
TOCOFERSOLAN
United Kingdom
WILZIN
ZINC ACETATE
Austria
WILZIN
ZINC ACETATE
Belgium
WILZIN
ZINC ACETATE
Bulgaria
WILZIN
ZINC ACETATE
Croatia
WILZIN
ZINC ACETATE
Cyprus
WILZIN
ZINC ACETATE
Czech Republic
WILZIN
ZINC ACETATE
Denmark
WILZIN
ZINC ACETATE
Estonia
WILZIN
ZINC ACETATE
Finland
WILZIN
ZINC ACETATE
France
WILZIN
ZINC ACETATE
Germany
WILZIN
ZINC ACETATE
Greece
WILZIN
ZINC ACETATE
Hungary
WILZIN
ZINC ACETATE
Iceland
WILZIN
ZINC ACETATE
Ireland
WILZIN
ZINC ACETATE
Italy
WILZIN
ZINC ACETATE
Latvia
WILZIN
ZINC ACETATE
Lichtenstein
WILZIN
ZINC ACETATE
Lithuania
WILZIN
ZINC ACETATE
Luxembourg
WILZIN
ZINC ACETATE
Malta
WILZIN
ZINC ACETATE
Netherlands
WILZIN
ZINC ACETATE
Norway
WILZIN
ZINC ACETATE
Poland
WILZIN
ZINC ACETATE
Portugal
WILZIN
ZINC ACETATE
Romania
WILZIN
ZINC ACETATE
Slovakia
WILZIN
ZINC ACETATE
Slovenia
WILZIN
ZINC ACETATE
Spain
WILZIN
ZINC ACETATE
Sweden
WILZIN
ZINC ACETATE
United Kingdom
No Products Found, please try another selection.

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

This website contains information about products that may not be available in all countries or may be available under different trademarks, for different indications, or in different doses. If you are a US resident please click the button below.

Stay on Global Site
Go to US site

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Şu anda bu siteden, Recordati Rare Diseases’e ait kurumsal bir web sayfasından ayrılıyorsunuz. Sağlık Profesyonelleri için bilgi.

KABUL ET
REDDET

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

Você está saindo deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

 

Está a sair deste site, um site corporativo da Recordati Rare Diseases, Informação para Profissionais de Saúde.

ACEITO
NĀO ACEITO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO
Ahora estás saliendo de este sitio, una página corporativa de Recordati Rare Diseases Iberia. Información para Profesionales Sanitarios.
ACEPTO
NO ACEPTO
Ahora estás saliendo de este sitio, una página corporativa de Recordati Rare Diseases Iberia. Información para Profesionales Sanitarios.
ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Le comunicamos que la ficha ténica / prospecto que aparece en el siguiente enlace es una información pública en la web de la Agenia Española de Medicamentos y Productos Sanitarios (AMPS).
¿Acepta abrir este enlace?

ACEPTO
NO ACEPTO

Réseau des Associations Vouées aux Troubles Sanguins Rares

The NRBDO is a pan Canadian coalition of not-for-profit organizations representing people with rare blood disorders and/or people with a chronic condition who are recipients of blood or blood products or their alternatives.

Visit website

Lymphoma Canada (Lymphome Canada)

Lorsque l’on est confronté à un lymphome, on se sent vite dépassé. Nous sommes une communauté au sein de laquelle on peut parler de cette maladie qui est le cinquième cancer le plus fréquent au Canada.

Visiter le site web

Acromégalie Canada

Acromégalie Canada est un organisme à but non lucratif fondé en 2019 pour rassembler les Canadiens dont la vie a été touchée par l’acromégalie. Notre mission est de sensibiliser à l’acromégalie et au gigantisme par l’éducation tout en offrant un réseau de soutien aux patients et à leurs familles à travers le Canada.

Visiter le site web

Global Genes

Global Genes est une organisation éminente de lutte contre les maladies rares. Sa mission consiste à sensibiliser et éduquer la communauté mondiale ainsi qu’à établir des relations importantes et à fournir des ressources essentielles permettant aux défenseurs de cette cause de s’engager pour lutter contre leur maladie.

Visiter le site web

Regroupement Québécois des Maladies Orphelines

Par l’entremise de son Centre d’information et de ressources en maladies rares, la RQMO fournit des renseignements et du soutien aux professionnels de la santé, aux patients qui souffrent de maladies rares et orphelines ainsi qu’à leur famille.

Visiter le site web

Collège canadien de généticiens médicaux

Le CCMG est une organisation nationale canadienne qui aide ses membres, les gouvernements et le public en assurant la certification des personnes, en établissant des normes, en dispensant des formations, et en guidant la politique d’intérêt public.

Visiter le site web

National Urea Cycle Disorders Foundation (NUCDF, fondation nationale pour les troubles du cycle de l'urée)

La NUCDF (fondation nationale pour les troubles du cycle de l’urée) est dédiée à l’identification, le traitement et la guérison des troubles du cycle de l’urée.

Visiter le site web

Canadian Organization for Rare Disorders (CORD, organisation canadienne pour les maladies rares)

La CORD (organisation canadienne pour les maladies rares) est le réseau national canadien des organisations représentant toutes les personnes atteintes de maladies rares. La CORD s’engage en vue de promouvoir une politique et un système de santé qui répondent aux besoins des personnes atteintes de maladies rares.

Visiter le site web

The Garrod Association (l'association Garrod)

The Garrod Association (l’association Garrod) est un organisme canadien permanent à l’échelle nationale dédié à la coordination de la gestion de maladies métaboliques héréditaires.

Visiter le site web

Association canadienne de porphyrie

L’Association canadienne de porphyrie s’engage à promouvoir la santé en permettant aux personnes atteintes de porphyrie d’avoir accès à un service de conseil et à des informations pertinentes ainsi qu’à des programmes de soutien de groupe.

Visiter le site web

Vous quittez Recordatiraredisease.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Vous quittez Recordatirarediseases.com :

Vous quittez recordatirarediseases.com, un site Web de Recordati Rare Diseases. Recordati Rare Diseases ne vérifie ni ne contrôle le contenu des sites Web externes. Les procédures de confidentialité de Recordati Rare Diseases ne s’appliquent pas aux sites Web externes et les hyperliens ne constituent pas une approbation par Recordati Rare Diseases du contenu du site Web externe.

OK
Annuler

Network of Rare Blood Disorder Organizations​

The NRBDO is a pan Canadian coalition of not-for-profit organizations representing people with rare blood disorders and/or people with a chronic condition who are recipients of blood or blood products or their alternatives.

Visit website

Lymphoma Canada

Dealing with lymphoma can be overwhelming. We are community that helps people talk about and cope with the fifth most common cancer in Canada.

Visit Website

Acromegaly Canada

Acromegaly Canada is a not-for-profit established in 2019 to bring together Canadians whose lives have been touched by acromegaly. Our mission: to raise awareness of acromegaly and gigantism through education while providing a network of support for patients and their families across Canada.

Visit Website

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK

Regroupement Québécois des Maladies Orphelines

Through its Center for Information and Resources on Rare Diseases, RQMO provides information and support to health professionals and to patients with rare and orphan diseases and their families.

Visit Website

Canadian College of Medical Geneticists

CCMG is a national Canadian organization that serves its members, governments and the public by certifying individuals, establishing standards, providing education, and informing public policy.

Visit Website

National Urea Cycle Disorders Foundation

The NUCDF is dedicated to the identification, treatment and cure of urea cycle disorders.

Visit website

Canadian Organization for Rare Disorders

CORD is Canada’s national network for organizations representing all those with rare disorders. CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders.
Visit Website

The Garrod Association

The Garrod Association is a permanent Canadian body at the national level for the coordination of the management of inherited metabolic disorders.
Visit Website

Global Genes

Global Genes is a leading rare disease advocacy organization. Their mission is to build awareness, educate the global community, and provide critical connections and resources that equip advocates to become activists for their disease.
Visit Website

Canadian Association for Porphyria

The Canadian Association for Porphyria is dedicated to promoting health by providing individuals with porphyria access to related counselling, information, and group support programs.
Visit Website

Leaving recordatirarediseases.com

You are now leaving recordatirarediseases.com
ACCEPT
GO BACK
Elisabeth Bergmans
Head of Legal

Elisabeth holds a master degree in corporate and commercial law from the University of Maastricht, and has 17 years experience in the legal profession. She began her career at the Benelux law firm Loyens & Loeff in Amsterdam where she specialized in Private Equity, banking & finance and insolvency & restructuring.


Feeling the need to work closer to the business, Elisabeth then held different positions as Legal Counsel in various industries, such as pension fund investment management, sustainable energy and a private equity fund. In 2015 she joined Teva Pharmaceuticals’ European headquarters in Amsterdam, covering over the years different roles with growing responsibilities; in her last remit she was General Counsel EU Commercial, responsible for the European regional legal support of innovative medicines and commercial HQ activities. In 2021, Elisabeth moved to Milan and continued her activities from there.


In September 2024 she joined Recordati as Head of Legal RRD where she is responsible for the global legal support of the Rare Diseases B.U.

Davide Paganoni
Head of Oncology Franchise

Davide is a biologist with more than 20 years of experience in the Health Care business with a broad commercial experience that ranges from rare disease to OTC.  He joined RRD in 2022, with the acquisition of EUSA, where he used to be Head of Europe and Global Marketing. Prior to EUSA Davide had more experiences as General Manager for biotech and pharma companies as Amryt and Exeltis and before he gained a strong experience in rare disease and ultra-specialistic areas covering senior commercial roles in highly recognized companies like Alexion and Astra Zeneca.

Aziza Johnson
Head of Regulatory Affairs

Aziza Johnson holds a Bachelor of Pharmacy from the London School of Pharmacy and a master’s degree in law from the University of Leicester. She is also a certified Board member, having completed the ZHAW Board of Directors program.

 

Aziza has over 27 years of experience in regulatory affairs, clinical development, and scientific strategy across global pharmaceutical companies and regulatory agencies. She has worked on numerous drug development programs, from clinical trials to market launches, with expertise in orphan drug development, regulatory compliance, and pharmacovigilance. Her career spans leadership roles in both the public and private sectors, including positions at Pfizer and the Medicines and Healthcare products Regulatory Agency (MHRA), where she honed her skills in pharmaceutical regulation and drug approval processes. She also facilitated over 25 successful acquisitions, expanded into new markets, and secured numerous regulatory approvals across the FDA, EMA, MHRA, CFDA, TGA, ANVISA, and Health Canada.

 

In 2023, Aziza joined Recordati Rare Diseases as Head of Regulatory Affairs, where she oversees global regulatory affairs for treatments targeting rare diseases. She leads efforts to secure regulatory approvals across diverse markets, ensuring patients with unmet medical needs receive timely access to innovative therapies.

Francesco Palombi
Head of Finance

Francesco Palombi is an experienced finance executive with over 25 years of global experience across pharmaceuticals, energy, and luxury goods. He holds a Master’s degree in Business Management from the University Cattolica del Sacro Cuore of Milan.

 

He began his career in 1997 at Price Waterhouse and later moved to ENI S.p.A. and Snam Rete Gas, where he managed financial audits, reporting, and external financial statements. In 2005, he joined Roche, advancing to roles including Head of Accounting & Credit Management, Head of Finance & Manufacturing Controlling, and Head of Controlling & Business Analysis.

 

In 2015, he became CFO of Roche Thailand & New Markets, managing finance across multiple countries. He later served as Global Head of Finance for Supply Chain and Product Strategy at Roche, leading financial strategy for global supply chain and product management, before assuming his current role as Global Finance Head at Recordati Rare Diseases in 2022.

Juan-Carlos Gerena
Group Supply Chain Head

Juan Carlos Gerena is a results-driven executive with over 20 years of global experience in manufacturing, supply chain, and business development across diverse industries, including FMCG, pharmaceuticals (branded and generics), and commodities. He has a proven track record of leading large-scale transformations, driving operational excellence, and managing complex end-to-end supply chains in multicultural and international environments.


Currently, as VP of Global Supply Chain at Recordati Group, Juan Carlos oversees the supply chain strategy for both Specialty Pharma and Rare Diseases divisions. Previously, he led global supply operations for renowned organizations like Sobi, Teva Pharmaceuticals, Galderma, Novartis, and Mylan, achieving major milestones such as scaling supply chains to support global expansion, integrating supply networks post-acquisition, and optimizing S&OP processes. His expertise spans strategic sourcing, logistics, CDMO management, pipeline scalability, and digital transformation.


A dynamic leader with a focus on delivering value and operational efficiency, he also played pivotal roles at Shell Oil Products Europe and Unilever, managing complex logistics optimization projects, refinery supply chains, and innovative process development initiatives.


Juan Carlos holds an MBA from the University of Houston and a Bachelor of Science in Industrial Engineering from the University of the Philippines. A skilled communicator, he is fluent in Spanish, English, Italian, and Filipino, with a working knowledge of German. His global mindset, technical expertise, and cultural adaptability make him an influential leader in driving sustainable business growth and supply chain resilience.

Gianni Paniale
Human Resources Director

Gianni holds a degree in Business Administration from Bocconi University in Milan and has built a versatile career spanning management consulting and the pharmaceutical industry.  His professional journey began in 1989 at Proudfoot, a management consulting firm specialising in productivity and quality improvements. Gianni took on progressively senior roles, eventually leading international projects across Italy, France, Germany, the UK, and the Czech Republic.


In 1997, he joined Recordati, initially responsible for the Organisation department, he later assumed leadership of human resources for the commercial organisation in Italy. In 2004, Gianni played a pivotal role in Recordati’s international expansion, leading HR efforts for acquisitions, start-ups and the consolidation of local affiliates.


In 2022, he was appointed Human Resources Director for the Rare Diseases business unit, where he oversaw HR strategies for this specialised and impactful division of the Group. His career reflects a deep commitment to fostering organisational growth and development on both a domestic and global scale.

Georg Thies
Head of Endocrinology Franchise

Georg Thies holds a diploma in Biology and has over 30 years of experience in the pharmaceutical industry.

 

His career in pharma started in 1984 with an apprenticeship at AMERSHAM BUCHLER. He later studied Biology at the GEORG-AUGUST UNIVERSITY in Göttingen and participated in the ERASMUS Program at the KING’S COLLEGE in London.

 

After 2,5 years of civil service, he continued his career at ROCHE in 1995, progressing from Key Account Manager to roles in National and International Marketing for Oncology products.

In 2002 he joined Amgen in Switzerland as International Brand Director for Oncology and Business Unit Head Oncology Switzerland. From 2008 onwards he worked as a Country Director for Sweden.

In 2011, Georg returned to Switzerland, gaining experience in Project- and New Product Planning. He was appointed European Brand Director Cardiovascular in 2012 and European Franchise Director General Medicine in 2014, overseeing Cardiology, Nephrology, Osteoporosis, and Inflammation.

In 2016, he joined SHIRE/TAKEDA, eventually becoming the Global Commercial Executive Director and later VP Global Program Lead in Endocrinology. He concluded his tenure at TAKEDA as Global Commercial Lead Gastrointestinal.

Since August 2022, Georg has been the VP RECORDATI Rare Disease Franchise Head Endocrinology.

Luca Setti
Corporate Portfolio Management Director

Luca Setti is the Corporate Portfolio Management Director at Recordati Rare Diseases, where he is responsible for the evaluation of business development opportunities, and the strategic guidance for life cycle management and pipeline projects.


Luca joined Recordati in July 2020 as Corporate Portfolio Manager, playing a pivotal role in the latest transactions performed by the company in the rare disease space, and in the management of pipeline projects.


Prior to joining Recordati, Luca worked for 10+ years in the business and corporate development departments of Alfasigma and Chiesi Farmaceutici, where he led the completion of multiple asset deals and licensing transactions.


Luca holds a Master’s Degree in Management Engineering from the Politecnico di Milano

Caring for the planet

A clean environment is essential for people’s well-being: the health of the planet and the health of people are closely connected. The air we breathe, the water we drink and the climate we live in all have an impact on our wellbeing. Focusing on people’s health and being sustainable also means prioritising environmental protection while behaving responsibly towards future generations.

 

This is why we ensure we conduct business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the demands of our stakeholders.

Caring for our communities

Contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely an obligation or professional duty for Recordati but a moral imperative.

 

We believe that caring for the communities in which we’re a part is essential to help them develop and grow, and to foster a sense of pride and belonging among our people.

Our Culture

The Recordati culture is built on the pillars of entrepreneurship, purpose and belonging; all have been part of our company since our beginnings in a small pharmacy in Northern Italy almost 100 years ago.

 

At the heart of our culture are our people, who are focused on always doing the right thing in the right way. We work together – across businesses, borders, time zones and national cultures – to support patients around the world in unlocking the full potential of life.

 

We give people the opportunity to develop themselves and bring their own unique ideas and perspectives to the table. Our culture is one where people can truly be the best versions of themselves, are safe to speak up and empowered to make decisions and experiment, learning as they go.

Diversity & Inclusion

Diversity is at the heart of our business and we do not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics.

 

We work hard to create a safe and inclusive work environment, respecting everyone’s right to physical and psychological integrity, as well as freedom of opinion and association. We know that we each of us has a role to play in the success of Recordati and each of us is rewarded for the unique contributions we make, regardless of who we are or where we come from.

Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is the Managing Director and General Manager for EMEA at Recordati Rare Diseases, where he oversees the company’s business operations across Europe, the Middle East, and North Africa. In this role, he is responsible for a broad range of functions, including Commercial, Medical Affairs, Marketing, and Market Access as well as key enabling areas such as Human Resources, Finance, Legal, Compliance to support the business’s growth and success.

 

Luigi joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. During his tenure, he played a pivotal role in driving the expansion of the company’s rare disease portfolio, leading efforts in business development, strategic marketing, and the management of pipeline projects.

 

Prior to joining Recordati, Luigi held senior positions in business and corporate development at Chiesi Farmaceutici and Menarini Group, where he successfully led numerous high-impact asset deals and transactions.

Luigi holds a degree in Economics from the University of Florence and a Master’s in Business Innovation from the prestigious Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region

Bruno Parenti is VP of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific, and Russia. He started opening new markets in 2012, spearheading the expansion of operations around the globe including the direct entry in Japan, China, South Korea, Australia, Brazil, Colombia, Mexico, and Argentina. In the last 2 years, he has successfully integrated the oncology portfolio in the Region, with new launches expanding the access to these life changing therapies to more and more patients.

 

From 2019 to 2022 he has held the additional role of Head of Global Endocrinology, establishing the new HQ in Basel, building from scratch a dedicated organization and coordinating the global launch of Isturisa and the re-launch of Signifor.

 

Prior to these positions, he spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Mohamed Ladha
President and General Manager, North America

Mohamed Ladha is the President and General Manager at Recordati Rare Diseases where he is  responsible for the US and Canadian business. During his career,  Mohamed has held numerous leadership positions globally in hematology/oncology and specialty care to oversee business in the US, Canada, EU, China, Emerging Markets, and Japan.

 

Mohamed  joins Recordati Rare Diseases from Oncopeptides, where he was the General Manager and Executive Vice President for the US Region Business Unit. Prior to Oncopeptides, he served in a series of leadership positions of increasing responsibility at companies including Vertex Pharmaceuticals, Pfizer, Schering-Plough, Merck & Company, Hospira, ARIAD Pharmaceuticals, Takeda Oncology, and Tocagen. He started his career in basic science research focused in oncology at the Dana-Farber Cancer Institute.

 

Mohamed graduated from Hampshire College with a Bachelor of Arts degree. He also holds professional/graduate degrees from Harvard University’s Kennedy School of Government and Northwestern University’s Kellogg School of Management.

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site